PFE is not a daily-fluctuation story for me right now.The bigger picture is more important.
On the monthly chart, PFE is sitting inside a long-term structural recovery area after years of decline from the 2021–2022 highs. Price is still weak in the short term, but the chart is no longer just about small daily moves. The bigger structure is showing something more interesting:
A potential long-term bullish sequence with a projected C target near $87.
That $87 area is not a quick swing target.
That is the higher-timeframe investing target.
This matters because there are two different maps here:
Daily chart = execution and timing.
Monthly chart = investment thesis and destination.
The current price is around $26.53, giving PFE a market cap near $152B. So if the monthly structure keeps building, the upside toward the HTF C target is meaningful — but only if price continues to respect the larger sequence.
From a structural perspective, I’m watching the monthly chart like this:
- Price has already reached an important lower reaction area.
- The monthly recovery attempt is still early.
- The larger bullish sequence points toward the $87 region.
- The current zone can become accumulation only if price keeps holding structure.
- Losing the base would delay the thesis and force patience.
The key mistake would be treating this like a normal short-term trade.
I don’t want to judge this chart candle by candle.
I want to judge it by monthly structure, recovery behavior, and whether the company can keep stabilizing fundamentally.
Fundamentally, Pfizer is not a hype stock right now. It is more of a large-cap pharma recovery and income setup. The company recently reaffirmed 2026 guidance of $59.5B–$62.5B revenue and $2.80–$3.00 adjusted EPS, while Q1 2026 revenue came in at $14.451B. That gives the recovery thesis some fundamental support, but not enough to blindly trust the stock without structure.
The dividend also gives investors a reason to stay interested. Pfizer declared a $0.43 quarterly dividend, marking its 350th consecutive quarterly dividend. That adds an income angle, but the dividend is not the trade. Structure is still the boss.
My bigger-picture read:
PFE is not a momentum stock yet.
It is a long-term recovery candidate sitting near a potential accumulation area.
The monthly target near $87 is the main attraction, but the stock has to earn that path. I want to see higher-timeframe strength develop, not just one bounce and excitement.
For now, the thesis is simple:
Ignore the daily noise.
Respect the monthly structure.
Let the recovery prove itself.
If the sequence holds, $87 becomes the bigger investing target.
This is the kind of setup where patience matters more than prediction.
Not financial advice.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, alım satım veya diğer türden tavsiye veya öneriler anlamına gelmez ve teşkil etmez. Kullanım Koşulları bölümünde daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, alım satım veya diğer türden tavsiye veya öneriler anlamına gelmez ve teşkil etmez. Kullanım Koşulları bölümünde daha fazlasını okuyun.